Employees with fibromyalgia: Medical comorbidity, healthcare costs, and work loss

Journal of Occupational and Environmental Medicine

Volumn 50, Issue 1, 2008, Pages 13-24

  White, Leigh Ann ^a   Birnbaum, Howard G ^a   Kaltenboeck, Anna ^a   Tang, Jackson ^a   Mallett, David ^b   Robinson, Rebecca L ^c  

^a ANALYSIS GROUP   (United States)

^b Ingenix Inc   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; CYCLOOXYGENASE 2 INHIBITOR; DULOXETINE; FLUOXETINE; GABAPENTIN; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; PREGABALIN; SALICYLIC ACID; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL PAIN; ABSENTEEISM; ADULT; ANXIETY DISORDER; ARTICLE; BACKACHE; BIPOLAR DISORDER; CHRONIC FATIGUE SYNDROME; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISABILITY; DRUG COST; ECONOMIC ASPECT; EMPLOYEE; FEMALE; FIBROMYALGIA; HEADACHE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIGRAINE; MUSCULOSKELETAL DISEASE; OSTEOARTHRITIS; PAIN; PRESCRIPTION; PREVALENCE; PRIVATE HEALTH INSURANCE; SLEEP DISORDER; THORAX PAIN;

EID: 38049152731     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e31815cff4b     Document Type: Article

References (26)

1. White KP, Harth M. Classification, epidemiology and natural history of fibromyalgia. Curr Pain Headache Rep. 2001;5:320-329.
2. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities. J Clin Rheumatol. 2006;12:124-128.
3. Robinson RL, Birnbaum HG, Morley MA, et al. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J Rheumatol. 2004;31:1621-1629.
4. Wolfe F, Ross K, Anderson J, Russell IJ, Herbert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19-28.
5. De Girolama G. Epidemiology and social costs of low back pain and fibromyalgia. Clin J Pain. 1991;7(suppl):S1-S7.
6. Walker EA, Keegan D, Gardner G, Sullivan M, Katon WJ, Bernstein D. Psychosocial factors in fibromyalgia compared with rheumatoid arthritis. I. Psychiatric diagnoses and functional disability. Psychosom Med. 1997;59:565-571.
7. Bernard AL, Prince A, Edsall P. Quality of life issues for fibromyalgia patients. Arthritis Care Res. 2000;13:42-50.
8. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ. Economic costs and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol. 2003;30:1318-1325.
9. Robinson RL, Jones ML. In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother. 2006;7:1-13.
10. White KP, Speechley M, Harth M, Ostbye T. The London fibromyalgia epidemiology study: direct health care costs of fibromyalgia syndrome in London, Canada. J Rheumatol. 1999;26:885-889.
11. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997;40:1560-1570.
12. Wolfe F, Anderson J, Harkness D, et al. Work and disability status of persons with fibromyalgia. J Rheumatol. 1997;24:1171-1178.
13. Penrod JR, Bernatsky S, Adam V, et al. Health service costs and their determinants in women with fibromyalgia. J Rheumatol. 2004;31:1391-1398.
14. Burckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. Glenview, IL: American Pain Society; 2005.
15. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388-2395.
16. Arnold LM. New therapies in fibromyalgia. Arthritis Res Ther. 2006;8:212-232.
17. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol. 2007;21:499-511.
18. Levine JD, Reichling DB. Fibromyalgia: the nerve of that disease. J Rheumatol. 2005;75(suppl):29-37.
19. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics. 2007;8:67-74.
20. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol. 2005;75(suppl):6-21.
21. White AG, Birnbaum HG, Mareva MN, et al. Economic burden of illness for employees with painful conditions. J Occup Environ Med. 2005;47:885-892.
22. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290:2443-2454.
23. America College of Rheumatology. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum. 2000;43:1905-1915.
24. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
25. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61:1498-1508.
26. Oliveria SA, Felson DT, Reed JI, et al. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum. 1995;38:1134-1141.